OGT has expanded its SureSeq Universal NGS Unique Dual Index portfolio, enabling up to 384 uniquely indexed samples per run on Illumina platforms, quadrupling previous capacity and supporting higher-throughput workflows, according to the company.
The expanded testing capabilities leverage long-read sequencing technology to detect disorders such as Fragile X syndrome, adult neurological conditions, certain ataxias, and more.
The circulating tumor DNA test is designed to identify MRD-positive patients with stage II colorectal cancer who may benefit from adjuvant therapy.
A new study reveals that a simple blood test using single-cell sequencing of rare stem cells can detect early signs of leukemia.
Read More
NGS-based MRD testing offers unprecedented sensitivity and breadth in detecting low-frequency leukemic clones.
Read More
mNGS significantly improves pathogen detection in pulmonary infections, enabling more precision compared to conventional methods.
Read More
NeoGenomics and Ultima Genomics have partnered to use the UG 100 sequencing platform to advance precision oncology diagnostics.
Read More
Bruker announced major advancements at ESCMID Global, including expanded PCR assay options for its BeGenius system.
Read More
Thermo Fisher Scientific has launched the One Lambda HybriType HLA Plus Typing Flex kit, an NGS hybrid capture assay.
Read More
Children’s Hospital Colorado’s new in-house whole-genome sequencing lab is revolutionizing patient care by making genetic testing faster.
Read More
Ultima Genomics has launched UG 100 Solaris, an upgraded sequencing solution that enhances throughput and reduces costs.
Read More
Researchers have developed a revolutionary method using DNA sequencing to rapidly and precisely measure metabolites critical for health.
Read More
Baylor Genetics has partnered with Epic’s Aura diagnostics suite, enabling ordering genetic tests and access results directly within the EHR.
Read More
Datar Cancer Genetics introduced a blood test that combines tumor-agnostic NGS and tumor-informed dd-PCR to detect MRD.
Read More
Researchers demonstrate the potential of long-read sequencing to diagnose rare genetic diseases faster and more accurately.
Read More
OGT’s SureSeq Myeloid MRD Panel offers a NGS solution for ultra-sensitive detection of MRD biomarkers in acute myeloid leukemia.
Read More
While serving the region, Doylestown Health has a small clinical laboratory. To better serve its community, it added NGS in 2023.Â
Read More
Two studies demonstrate the potential of a genomic screening platform to improve early detection of genetic diseases in newborns.
Read More